Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.72 |
| ▸ | EZH1 | Q92800 | 4/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | EED | O75530 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.61 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.61 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14717843 | 0.94 | EZH2 (0.70) | EZH2EZH1NR1I2EEDABCB11 | |
| SCHEMBL2589143 | 0.89 | EZH2 (0.70) | EZH2EZH1EEDSUZ12 | |
| SCHEMBL19620940 | 0.89 | EZH2 (0.66) | EZH2EZH1EEDSUZ12 | |
| SCHEMBL2594597 | 0.86 | EZH2 (0.61) | EZH2EZH1EEDSUZ12 | |
| SCHEMBL12180083 | 0.85 | EZH2 (0.85) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL19620729 | 0.85 | EZH2 (0.70) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL2594531 | 0.85 | EZH2 (0.58) | EZH2EZH1 | |
| SCHEMBL14717553 | 0.84 | EZH2 (0.71) | EZH2EZH1EEDSUZ12 | |
| SCHEMBL2594806 | 0.84 | EZH2 (0.75) | EZH2EZH1EEDSUZ12 | |
| SCHEMBL23030040 | 0.84 | EZH2 (0.72) | EZH2EZH1NR1I2EEDABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |